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Background: Third-degree atrio-ventricular block (AVB) is a frequent complication
following transcatheter aortic valve implantation (TAVI) with the Corevalve prosthesis.
Previous observational studies relate AVB to a lower implantation of the prosthesis
into the left ventricle outflow tract (LVOT), indirectly suggesting that AVB may be the
result of direct mechanical damage to the conduction system. Our aim is to analyze
whether the final position of the Corevalve prosthesis in relation to the His bundle is
indeed related to new onset AVB.
Methods: In 24 permanent-pacemaker-free patients (P) undergoing TAVI, a tetrapolar
catheter was used to identify the intracavitary electrograms of the His bundle and as a
marker of the His bundle position. Two independent readers analyzed the relative
position of the inferior border of the Corevalve prosthesis (IBCVP) and the tip of the
His-bundle catheter (THBC) (above or below) at the end of the procedure in three
fluoroscopy projections. Baseline electrocardiographic (EKG) conduction anomalies
(AV and bundle branch blocks) and 3rd-degree AVB development during TAVI were
also recorded for each P. This is a partial analysis of a more extensive study involving
EPS stimulation immediately before and after Corevalve implantation. All P signed
informed. PAWS 18 was used for statistical analysis.
Results: Two P were excluded from the analysis because the relative position of the
IBCVP and the THBC suffered continuous variations along the cardiac cycle. The
IBCVP was identified below the level of the THBC in 6P (group A) and above this
level in the remaining 16 (group B). 3rd-degree AVB developed in 27% P following
TAVI (in 67% P in group A and in 12,5% P in group B, p=0.025). No baseline EKG
anomaly was related to 3rd-degree AVB development, probably due to the small sample
size.
Conclusion: 3rd-degree AVB after Corevalve TAVI is related to prosthesis extension
below the His bundle level. This study supports that the higher incidence of AVB
reported in those P with a lower implantation of the prosthesis in the LVOT is due to
direct damage to the His bundle system.
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Background: Measurement of the aortic annulus is crucial for appropriate valve sizing
in transcatheter aortic valve implantation (TAVI). The purpose of this study was to
clarify the impact of CT-guided valve sizing on outcomes after TAVI.
Methods: TAVI was performed in 337 consecutive cases in our institution.
Transesophageal echo (TEE)-guided valve sizing was conducted in our early
experience (n=228). CT-guided approach has been applied since 2010 (n=109). The
CT-measured mean annulus diameter was calculated as: mDiam-CT = 2√(annulus
surface/√). The outcomes of both strategies were compared.
Results: The CT group had lower Euroscore (20.6±10.8% vs 24.8±11.5%, p=0.002),
higher eGFR (58.6±22.6 vs 49.8±24.2ml/min, p=0.002) and left ventricular ejection
fraction (58.6±22.6 vs 49.8±24.2, p=0.002). TEE-measured annulus diameter (Diam-
TEE) was similar (22.1±2.0 vs 21.8±1.8mm, p=0.155). In the CT group, the Diam-TEE
was larger than the shortest CT diameter (22.1±2.0 vs 21.7±2.0mm, p=0.008), but
smaller than mDiam-CT (23.4±2.0mm, p<0.001) and largest CT diameter
(25.9±2.3mm, p<00001). The Edwards valve was used in 290 cases (23mm in 42%,
26mm 56% and 29mm 2%) and Corevalve in 47 (26mm in 26% and 29mm in 74%).
Edwards valves were used similarly in both groups (84% vs 87%, p=0.547). The CT
group had significantly larger valve size (25.8±2.1 vs 25.0±1.9mm, p<0.001) and larger
valve/Diam-TEE ratio (1.17±0.08 vs 1.14±0.10mm, p=0.014) compared to TEE group.
Although post dilatation was required similarly in both groups (12.7 vs 10.8%,
p=0.506), the incidence of post-procedural AR ≥2 was decreased in CT group (19.1 vs
30.7%, p=0.031) without any increase in annulus rupture (0.9 vs 1.3%, p=0.750) and
conversion to surgery was less often required in CT group (0% vs 3.5%, p=0.004).
Conclusion: CT-guided strategy provides larger valve sizing compared to TEE with
appropriate accuracy, resulting in a significantly lower incidence of post-procedural
AR without any increase in annulus rupture.
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Background: No data has been published previously comparing the outcomes of
transcatheter aortic valve replacement (TAVR) by commonly used surgical risk
stratification scores.
Methods: All consecutive patients from our single-center prospective registry treated
by TAVR transfemorally for aortic stenosis from November 2007 to April 2011,
utilizing both commercially available valves were analyzed. Patients were categorized
into low-, intermediate- and high-risk categories according to STS-PROM Score (STS)
(<3, 3-8, >8) or Logistic EuroSCORE (LogES) (<10%, 10-20%, >20%). Study
endpoints were defined by the Valve Academic Research Consortium (VARC)
definitions.
Results: 249 patients were included: mean age 79.7±7.5 years and 63.5% Edwards
SAPIEN™. According to STS, there were 18.5% patients in the low-, 54.2% in the
intermediate- and 27.3% in the high-risk category. According to LogES, there were
22.1% patients in the low-, 31.3% in the intermediate- and 46.6% in the high-risk
category. Thirty-day mortality was 4.1% overall with no differences according to risk
stratification: according to STS 6.8% in low- vs. 2.3% in intermediate- vs. 6.1% in
high-risk (p=0.271). According to LogES 3.9% in low- vs. 1.3% in intermediate- vs.
6.1% in high-risk; p=0.250. Both high-risk groups developed more acute kidney injury
stage 3: respectively in high risk STS 20.6% and in high risk LogES 13.8%. Moreover,
there was a trend towards more life-threatening bleeding in the high-risk STS category
(16.6% vs. 19.3% vs. 33.8%; p=0.055). There were no other differences in VARC
safety and efficacy endpoints or combined safety endpoint at 30 days between groups.
Conclusion: Neither STS or LogES are predictors of 30-day mortality in patients
undergoing TAVR. New scores need to be developed to help risk stratify these patients.
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Geometry of the Edwards SAPIEN XT valve as assessed by Multidetector
Computed Tomography
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Background: The SAPIEN XT aortic bioprosthesis is the balloon expandable valve
of choice for transcatheter aortic valve replacement (TAVR) due to its lower profile
delivery system. This has been made possible, in part, by design and material changes
to the frame. Clinical evaluation of the effect of these design modifications on radial
expansion and circularity is lacking. We assessed the geometry of the SAPIEN XT
bioprosthesis with multidetector computed tomography (MDCT) and correlated these
findings with early clinical events.
Methods: MDCT was performed in 49 patients within one week of SAPIEN XT valve
implantation. Geometry of the stent frame was assessed for circularity, minimum
(Dmin) and maximum (Dmax) external diameter and expansion ratio at three stent
levels: inflow, mid and outflow. Circularity was defined as an eccentricity index (EI)
of less than 0.1 (EI = 1-Dmin/Dmax) and expansion ratio (ER) as the MDCT derived
stent area divided by the area of a fully expanded valve. Valve/annular malapposition
on MDCT and grade of paravalvular aortic regurgitation (PR) on TEE were assessed.
Results: Stents were circular in 95.9% of cases (47/49). The mean expansion ratio was
105.1+7.2% with no valves having an ER of less than 90%. The mean external diameter
for the 20,23,26 and 29mm valves was 20.0+1.0mm, 23.5+1.1mm, 25.9+0.7mm and
29.0+1.0mm respectively. There was no difference in circularity or expansion ratio
from the inflow to outflow aspect of the stents (EI : 0.02 vs. 0.02,p=0.75, ER: 104.8%
vs.106.5%, p=0.26). There was no difference in expansion or circularity in patients
with moderate to severe valvular PR compared to trace/mild PR (ER: 108.4% vs.
105.3%, p= 0.37, EI: 0.05 vs. 0.02, p=0.40). Annular malapposition (12/43, 27.9%) on
MDCT was associated with moderate to severe valvular PR in 21.4%(3/14) compared
with 5.7% (2/35) with circumferential annular apposition (p=0.12).
Conclusion: The early structural integrity of the SAPIEN XT valve is excellent as
demonstrated by full expansion and circularity across all stent levels. Malapposition
on MDCT may be associated with paravalvular aortic regurgitation.
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